Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. Circulation. 2010;121:916–28.

Article  PubMed  Google Scholar 

Imazio M, Brucato A, Adler Y. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2014;370:781.

CAS  PubMed  Google Scholar 

Klein AL, Imazio M, Brucato A, et al. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis. Am Heart J. 2020;228:81–90.

Article  CAS  PubMed  Google Scholar 

US.FDA. Drugs@FDA: FDA-Approved Drugs. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125249s049lbl.pdf. Accessed 21 Aug 2024.

Brucato A, Brambilla G, Moreo A, et al. Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J Cardiol. 2006;98:267–71.

Article  PubMed  Google Scholar 

Klein A, Cremer P, Kontzias A, et al. US database study of clinical burden and unmet need in recurrent pericarditis. J Am Heart Assoc. 2021;10: e18950.

Article  Google Scholar 

Lin D, Laliberté F, Majeski C, et al. Disease and economic burden associated with recurrent pericarditis in a privately insured united states population. Adv Ther. 2021;38:5127–43.

Article  PubMed  PubMed Central  Google Scholar 

Imazio M, Klein AL, Brucato A, et al. sustained pericarditis recurrence risk reduction with long-term rilonacept. J Am Heart Assoc. 2024;13: e32516.

Article  Google Scholar 

Chi Z, Bai X, Zhang Z. Adverse reaction signals mining of vonoprazan: a pharmacovigilance study based on FAERS. J Clin Pharm Ther. 2023;2023:7588085.

Article  Google Scholar 

Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. 2017;26:2333–55.

Article  PubMed  Google Scholar 

Davey SG, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23:R89-98.

Article  Google Scholar 

Swanson SA, Tiemeier H, Ikram MA, et al. Nature as a trialist?: Deconstructing the analogy between Mendelian randomization and randomized trials. Epidemiology. 2017;28:653–9.

Article  PubMed  PubMed Central  Google Scholar 

Nitsch D, Molokhia M, Smeeth L, et al. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol. 2006;163:397–403.

Article  PubMed  Google Scholar 

FDA. Food and Drug Administration Adverse Event Reporting System (FAERS). [Online]. Available at: https://open.fda.gov/data/faers/. Accessed 21 Aug 2024.

Medical Dictionary for Regulatory Activities. Standardised MedDRA queries. https://www.meddra.org/standardised-meddra-queries. Accessed 21 Aug 2024.

Anand K, Ensor J, Trachtenberg B, et al. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS). JACC CardioOncol. 2019;1:172–8.

Article  PubMed  PubMed Central  Google Scholar 

Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519–23.

Article  PubMed  Google Scholar 

Zou F, Cui Z, Lou S, et al. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol. 2024;15:1338902.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trippe ZA, Brendani B, Meier C, et al. Identification of substandard medicines via disproportionality analysis of individual case safety reports. Drug Saf. 2017;40:293–303.

Article  CAS  PubMed  Google Scholar 

Lazaros G, Tsioufis K, Vassilopoulos D. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med. 2021;384:1474–5.

Article  PubMed  Google Scholar 

Dewberry RM, Crossman DC, Francis SE. Interleukin-1 receptor antagonist (IL-1RN) genotype modulates the replicative capacity of human endothelial cells. Circ Res. 2003;92:1285–7.

Article  CAS  PubMed  Google Scholar 

Thorolfsdottir RB, Jonsdottir AB, Sveinbjornsson G, et al. Variants at the interleukin 1 gene locus and pericarditis. JAMA Cardiol. 2024;9:165–72.

Article  PubMed  Google Scholar 

Xie W, Li J, Du H, et al. Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study. Arthritis Res Ther. 2023;25:148.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao SS, Yiu Z, Barton A, et al. association of lipid-lowering drugs with risk of psoriasis: a Mendelian randomization study. JAMA Dermatol. 2023;159:275–80.

Article  PubMed  PubMed Central  Google Scholar 

Niu Q, Zhang T, Mao R, et al. Genetic association of lipid and lipid-lowering drug target genes with atopic dermatitis: a drug target Mendelian randomization study. Sci Rep. 2024;14:18097.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li B, Martin EB. An approximation to the F distribution using the chi-square distribution. Comput Stat Data Anal. 2002;40:21–6.

Article  Google Scholar 

Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40:755–64.

Article  PubMed  Google Scholar 

Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol. 2013;178:1177–84.

Article  PubMed  PubMed Central  Google Scholar 

Bowden J, Davey SG, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512–25.

Article  PubMed  PubMed Central  Google Scholar 

Bowden J, Davey SG, Haycock PC, et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40:304–14.

Article  PubMed  PubMed Central  Google Scholar 

Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377–89.

Article  PubMed  PubMed Central  Google Scholar 

Soler-Soler J, Sagristà-Sauleda J, Permanyer-Miralda G. Relapsing pericarditis. Heart. 2004;90:1364–8.

Article  PubMed  PubMed Central  Google Scholar 

Imazio M, Cecchi E, Ierna S, et al. CORP (COlchicine for Recurrent Pericarditis) and CORP-2 trials–two randomized placebo-controlled trials evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of recurrent pericarditis: study design and rationale. J Cardiovasc Med (Hagerstown). 2007;8:830–4.

Article  PubMed  Google Scholar 

Khandaker MH, Espinosa RE, Nishimura RA, et al. Pericardial disease: diagnosis and management. Mayo Clin Proc. 2010;85:572–93.

Article  PubMed  PubMed Central  Google Scholar 

Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155:409–14.

Article  PubMed  Google Scholar 

Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383:2232–7.

Article  CAS  PubMed  Google Scholar 

Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and managem